Bavarian Nordic sells discount shares to help fund Covid-19 vaccine

Bavarian Nordic has sold shares worth DKK 1.1bn (USD 175.8m) at DKK 223 per share, which will partly go towards financing the company's further development of the Covid-19 vaccine which the firm has in-licensed from Adaptvac.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app